Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis

Fiona D M Van Schaik, Bas Oldenburg, G. Johan A Offerhaus, Marguerite E I Schipper, Frank P. Vleggaar, Peter D. Siersema, Martijn G H Van Oijen, Fiebo J W Ten Kate

Research output: Contribution to journalArticle

Abstract

Background: Although dysplasia is thought to be the precursor lesion in the development of colitis-associated colorectal cancer (CRC), a significant proportion of patients with ulcerative colitis (UC) and low-grade (LGD) or indefinite (IND) dysplasia remain cancer-free during endoscopic follow-up. There is a need for biomarkers that predict neoplastic progression. We studied the value of a series of immunohistochemical markers in UC patients with flat LGD or IND with regard to neoplastic progression. Methods: Tissue samples were collected from 12 UC patients (six flat LGD, six IND) without progression and from 10 UC patients (eight flat LGD, two IND) with documented progression to HGD and/or CRC during a median of 25 and 23 months of colonoscopic follow-up, respectively. Immunohistochemistry using monoclonal antibodies was performed for p53, CD44, Ki67, AMACR, β-catenin, cyclin D1, p21, and ALDH. Positive and negative staining patterns were compared for progression to advanced neoplasia. Results: When patients showed coexpression of p53 and AMACR, 6/7 patients (86%) developed advanced neoplasia, compared to 4/15 patients (27%) without p53/AMACR coexpression (P = 0.02). Patients with p53/AMACR coexpression developed advanced neoplasia in a time period of 19 months (median, range 1-101) compared to 80 months (median, range 8-169) in patients without p53/AMACR coexpression (P = 0.14). Interestingly, in three patients with progression and previous dysplasia-negative biopsies, two out of three biopsies were p53-positive a median of 12 months (range 10-14) before the LGD/IND diagnosis. Conclusions: This study suggests a role for p53/AMACR coexpression as a potential marker of neoplastic progression in patients with UC.

Original languageEnglish (US)
Pages (from-to)480-488
Number of pages9
JournalInflammatory Bowel Diseases
Volume18
Issue number3
DOIs
StatePublished - Mar 2012
Externally publishedYes

Fingerprint

Ulcerative Colitis
Neoplasms
Colorectal Neoplasms
Biopsy
Catenins
Negative Staining
Cyclin D1
Colitis
Biomarkers
Immunohistochemistry
Monoclonal Antibodies

Keywords

  • immunohistochemistry
  • neoplasia
  • ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology
  • Immunology and Allergy

Cite this

Van Schaik, F. D. M., Oldenburg, B., Offerhaus, G. J. A., Schipper, M. E. I., Vleggaar, F. P., Siersema, P. D., ... Ten Kate, F. J. W. (2012). Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis. Inflammatory Bowel Diseases, 18(3), 480-488. https://doi.org/10.1002/ibd.21722

Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis. / Van Schaik, Fiona D M; Oldenburg, Bas; Offerhaus, G. Johan A; Schipper, Marguerite E I; Vleggaar, Frank P.; Siersema, Peter D.; Van Oijen, Martijn G H; Ten Kate, Fiebo J W.

In: Inflammatory Bowel Diseases, Vol. 18, No. 3, 03.2012, p. 480-488.

Research output: Contribution to journalArticle

Van Schaik, FDM, Oldenburg, B, Offerhaus, GJA, Schipper, MEI, Vleggaar, FP, Siersema, PD, Van Oijen, MGH & Ten Kate, FJW 2012, 'Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis', Inflammatory Bowel Diseases, vol. 18, no. 3, pp. 480-488. https://doi.org/10.1002/ibd.21722
Van Schaik, Fiona D M ; Oldenburg, Bas ; Offerhaus, G. Johan A ; Schipper, Marguerite E I ; Vleggaar, Frank P. ; Siersema, Peter D. ; Van Oijen, Martijn G H ; Ten Kate, Fiebo J W. / Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis. In: Inflammatory Bowel Diseases. 2012 ; Vol. 18, No. 3. pp. 480-488.
@article{692748b1832540dfbb8dcfb5e8830d6f,
title = "Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis",
abstract = "Background: Although dysplasia is thought to be the precursor lesion in the development of colitis-associated colorectal cancer (CRC), a significant proportion of patients with ulcerative colitis (UC) and low-grade (LGD) or indefinite (IND) dysplasia remain cancer-free during endoscopic follow-up. There is a need for biomarkers that predict neoplastic progression. We studied the value of a series of immunohistochemical markers in UC patients with flat LGD or IND with regard to neoplastic progression. Methods: Tissue samples were collected from 12 UC patients (six flat LGD, six IND) without progression and from 10 UC patients (eight flat LGD, two IND) with documented progression to HGD and/or CRC during a median of 25 and 23 months of colonoscopic follow-up, respectively. Immunohistochemistry using monoclonal antibodies was performed for p53, CD44, Ki67, AMACR, β-catenin, cyclin D1, p21, and ALDH. Positive and negative staining patterns were compared for progression to advanced neoplasia. Results: When patients showed coexpression of p53 and AMACR, 6/7 patients (86{\%}) developed advanced neoplasia, compared to 4/15 patients (27{\%}) without p53/AMACR coexpression (P = 0.02). Patients with p53/AMACR coexpression developed advanced neoplasia in a time period of 19 months (median, range 1-101) compared to 80 months (median, range 8-169) in patients without p53/AMACR coexpression (P = 0.14). Interestingly, in three patients with progression and previous dysplasia-negative biopsies, two out of three biopsies were p53-positive a median of 12 months (range 10-14) before the LGD/IND diagnosis. Conclusions: This study suggests a role for p53/AMACR coexpression as a potential marker of neoplastic progression in patients with UC.",
keywords = "immunohistochemistry, neoplasia, ulcerative colitis",
author = "{Van Schaik}, {Fiona D M} and Bas Oldenburg and Offerhaus, {G. Johan A} and Schipper, {Marguerite E I} and Vleggaar, {Frank P.} and Siersema, {Peter D.} and {Van Oijen}, {Martijn G H} and {Ten Kate}, {Fiebo J W}",
year = "2012",
month = "3",
doi = "10.1002/ibd.21722",
language = "English (US)",
volume = "18",
pages = "480--488",
journal = "Inflammatory Bowel Diseases",
issn = "1078-0998",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis

AU - Van Schaik, Fiona D M

AU - Oldenburg, Bas

AU - Offerhaus, G. Johan A

AU - Schipper, Marguerite E I

AU - Vleggaar, Frank P.

AU - Siersema, Peter D.

AU - Van Oijen, Martijn G H

AU - Ten Kate, Fiebo J W

PY - 2012/3

Y1 - 2012/3

N2 - Background: Although dysplasia is thought to be the precursor lesion in the development of colitis-associated colorectal cancer (CRC), a significant proportion of patients with ulcerative colitis (UC) and low-grade (LGD) or indefinite (IND) dysplasia remain cancer-free during endoscopic follow-up. There is a need for biomarkers that predict neoplastic progression. We studied the value of a series of immunohistochemical markers in UC patients with flat LGD or IND with regard to neoplastic progression. Methods: Tissue samples were collected from 12 UC patients (six flat LGD, six IND) without progression and from 10 UC patients (eight flat LGD, two IND) with documented progression to HGD and/or CRC during a median of 25 and 23 months of colonoscopic follow-up, respectively. Immunohistochemistry using monoclonal antibodies was performed for p53, CD44, Ki67, AMACR, β-catenin, cyclin D1, p21, and ALDH. Positive and negative staining patterns were compared for progression to advanced neoplasia. Results: When patients showed coexpression of p53 and AMACR, 6/7 patients (86%) developed advanced neoplasia, compared to 4/15 patients (27%) without p53/AMACR coexpression (P = 0.02). Patients with p53/AMACR coexpression developed advanced neoplasia in a time period of 19 months (median, range 1-101) compared to 80 months (median, range 8-169) in patients without p53/AMACR coexpression (P = 0.14). Interestingly, in three patients with progression and previous dysplasia-negative biopsies, two out of three biopsies were p53-positive a median of 12 months (range 10-14) before the LGD/IND diagnosis. Conclusions: This study suggests a role for p53/AMACR coexpression as a potential marker of neoplastic progression in patients with UC.

AB - Background: Although dysplasia is thought to be the precursor lesion in the development of colitis-associated colorectal cancer (CRC), a significant proportion of patients with ulcerative colitis (UC) and low-grade (LGD) or indefinite (IND) dysplasia remain cancer-free during endoscopic follow-up. There is a need for biomarkers that predict neoplastic progression. We studied the value of a series of immunohistochemical markers in UC patients with flat LGD or IND with regard to neoplastic progression. Methods: Tissue samples were collected from 12 UC patients (six flat LGD, six IND) without progression and from 10 UC patients (eight flat LGD, two IND) with documented progression to HGD and/or CRC during a median of 25 and 23 months of colonoscopic follow-up, respectively. Immunohistochemistry using monoclonal antibodies was performed for p53, CD44, Ki67, AMACR, β-catenin, cyclin D1, p21, and ALDH. Positive and negative staining patterns were compared for progression to advanced neoplasia. Results: When patients showed coexpression of p53 and AMACR, 6/7 patients (86%) developed advanced neoplasia, compared to 4/15 patients (27%) without p53/AMACR coexpression (P = 0.02). Patients with p53/AMACR coexpression developed advanced neoplasia in a time period of 19 months (median, range 1-101) compared to 80 months (median, range 8-169) in patients without p53/AMACR coexpression (P = 0.14). Interestingly, in three patients with progression and previous dysplasia-negative biopsies, two out of three biopsies were p53-positive a median of 12 months (range 10-14) before the LGD/IND diagnosis. Conclusions: This study suggests a role for p53/AMACR coexpression as a potential marker of neoplastic progression in patients with UC.

KW - immunohistochemistry

KW - neoplasia

KW - ulcerative colitis

UR - http://www.scopus.com/inward/record.url?scp=84857368717&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857368717&partnerID=8YFLogxK

U2 - 10.1002/ibd.21722

DO - 10.1002/ibd.21722

M3 - Article

C2 - 21509910

AN - SCOPUS:84857368717

VL - 18

SP - 480

EP - 488

JO - Inflammatory Bowel Diseases

JF - Inflammatory Bowel Diseases

SN - 1078-0998

IS - 3

ER -